Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of CCX168 in Healthy Volunteers
NCT06004947Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 cohorts), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration at Day 14, Time of Maximum Plasma Concentration at Day 14 and 2 more. Started Jan 2016; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06004947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004947.